AU2003253350B2 - Use of alkyl phosphocholines in combination with antitumor medicaments - Google Patents

Use of alkyl phosphocholines in combination with antitumor medicaments Download PDF

Info

Publication number
AU2003253350B2
AU2003253350B2 AU2003253350A AU2003253350A AU2003253350B2 AU 2003253350 B2 AU2003253350 B2 AU 2003253350B2 AU 2003253350 A AU2003253350 A AU 2003253350A AU 2003253350 A AU2003253350 A AU 2003253350A AU 2003253350 B2 AU2003253350 B2 AU 2003253350B2
Authority
AU
Australia
Prior art keywords
treatment
combination
benign
oxaliplatin
fludarabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003253350A
Other languages
English (en)
Other versions
AU2003253350A1 (en
Inventor
Jurgen Engel
Eckhard Gunther
Herbert Sindermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Aeterna Zentaris GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeterna Zentaris GmbH filed Critical Aeterna Zentaris GmbH
Publication of AU2003253350A1 publication Critical patent/AU2003253350A1/en
Application granted granted Critical
Publication of AU2003253350B2 publication Critical patent/AU2003253350B2/en
Priority to AU2008203060A priority Critical patent/AU2008203060B2/en
Assigned to AETERNA ZENTARIS GMBH reassignment AETERNA ZENTARIS GMBH Request to Amend Deed and Register Assignors: ZENTARIS GMBH
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003253350A 2002-07-30 2003-07-29 Use of alkyl phosphocholines in combination with antitumor medicaments Ceased AU2003253350B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008203060A AU2008203060B2 (en) 2002-07-30 2008-07-10 Use of alkyl phosphocholines in combination with antitumor medicaments

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39961502P 2002-07-30 2002-07-30
US60/399,615 2002-07-30
PCT/EP2003/008346 WO2004012744A1 (de) 2002-07-30 2003-07-29 Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008203060A Division AU2008203060B2 (en) 2002-07-30 2008-07-10 Use of alkyl phosphocholines in combination with antitumor medicaments

Publications (2)

Publication Number Publication Date
AU2003253350A1 AU2003253350A1 (en) 2004-02-23
AU2003253350B2 true AU2003253350B2 (en) 2008-06-26

Family

ID=31495746

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003253350A Ceased AU2003253350B2 (en) 2002-07-30 2003-07-29 Use of alkyl phosphocholines in combination with antitumor medicaments
AU2008203060A Ceased AU2008203060B2 (en) 2002-07-30 2008-07-10 Use of alkyl phosphocholines in combination with antitumor medicaments

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008203060A Ceased AU2008203060B2 (en) 2002-07-30 2008-07-10 Use of alkyl phosphocholines in combination with antitumor medicaments

Country Status (26)

Country Link
US (3) US8389497B2 (cg-RX-API-DMAC10.html)
EP (2) EP1545553B1 (cg-RX-API-DMAC10.html)
JP (1) JP2005535688A (cg-RX-API-DMAC10.html)
KR (3) KR101066804B1 (cg-RX-API-DMAC10.html)
CN (1) CN1302780C (cg-RX-API-DMAC10.html)
AR (1) AR040717A1 (cg-RX-API-DMAC10.html)
AT (1) ATE516036T1 (cg-RX-API-DMAC10.html)
AU (2) AU2003253350B2 (cg-RX-API-DMAC10.html)
BR (1) BR0313048A (cg-RX-API-DMAC10.html)
CA (1) CA2493023C (cg-RX-API-DMAC10.html)
CY (1) CY1111902T1 (cg-RX-API-DMAC10.html)
DK (1) DK1545553T3 (cg-RX-API-DMAC10.html)
ES (1) ES2369535T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20050184B1 (cg-RX-API-DMAC10.html)
IL (1) IL166329A (cg-RX-API-DMAC10.html)
MX (1) MXPA05001203A (cg-RX-API-DMAC10.html)
NO (1) NO335196B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ538428A (cg-RX-API-DMAC10.html)
PL (1) PL375493A1 (cg-RX-API-DMAC10.html)
PT (1) PT1545553E (cg-RX-API-DMAC10.html)
RU (1) RU2005105693A (cg-RX-API-DMAC10.html)
SI (1) SI1545553T1 (cg-RX-API-DMAC10.html)
TW (1) TWI332007B (cg-RX-API-DMAC10.html)
UA (1) UA82322C2 (cg-RX-API-DMAC10.html)
WO (1) WO2004012744A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200500453B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
UA82322C2 (uk) 2002-07-30 2008-04-10 Центаріс Гмбх Застосування алкілфосфохолінів в комбінації з протипухлинними лікарськими засобами
DE10324911B4 (de) 2003-05-30 2005-08-18 Siemens Ag Röntgenvorrichtung mit partiellem digitalem Detektor und Verfahren zum Betrieb einer solchen
WO2006081452A2 (en) * 2005-01-28 2006-08-03 Robert Birch Co-administration of perifosine with chemotherapeutics
EP1962862B1 (en) * 2005-12-19 2013-09-04 Æterna Zentaris GmbH Alkyl phospholipid derivatives with reduced cytotoxicity and uses therof
US20070167408A1 (en) * 2005-12-19 2007-07-19 Zentaris Gmbh Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
EP1800684A1 (en) * 2005-12-20 2007-06-27 Zentaris GmbH Novel alkyl phospholipid derivatives and uses thereof
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
CN103479604B (zh) * 2007-07-30 2016-08-10 阿迪生物科学公司 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法
AU2009324464B2 (en) * 2008-12-11 2016-05-05 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US8383607B2 (en) 2010-03-31 2013-02-26 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2086026T3 (es) * 1991-07-04 1996-06-16 Asta Medica Ag Farmaco con efecto antineoplasico que contiene como sustancia activa (2-(n-metil-piperidino)-etil)-fosfato de octadecilo y procedimiento para su preparacion.
US5942639A (en) * 1991-07-04 1999-08-24 Asta Medica Aktiengesellschaft Process for the preparation of alkylphosphocholines and the production thereof in pure form
US6172050B1 (en) * 1992-07-11 2001-01-09 Asta Medica Aktiengesellschaft Phospholipid derivatives
JP3079993B2 (ja) * 1996-03-27 2000-08-21 日本電気株式会社 真空マイクロデバイスおよびその製造方法
DE19650778C2 (de) * 1996-12-06 2001-01-04 Asta Medica Ag Verwendung von Dopaminrezeptor-Antagonisten in der palliativen Tumortherapie
CA2318260C (en) 1998-01-22 2006-11-21 Asta Medica Ag Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
JP2002531534A (ja) * 1998-12-04 2002-09-24 マックス−デルブルック−セントラム フュール モレクラーレ メディツィン タモキシフェン含有リポソーム系腫瘍治療剤
US6583127B1 (en) 1998-12-21 2003-06-24 Inkeysa. Sa Use of etherlysophospholipids as antiinflammatory agents
CN1551767A (zh) * 2001-02-19 2004-12-01 ��˹��ŵ�� 癌症的治疗
ATE450265T1 (de) * 2001-03-23 2009-12-15 Shire Canada Inc Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
WO2003005522A1 (es) 2001-07-04 2003-01-16 Acuna Arturo Tapones para sellado de ductos para redes electricas, telefonicas y de fibra optica.
DE60210329T2 (de) * 2002-01-02 2006-11-30 Nerviano Medical Sciences S.R.L., Nerviano Kombinierte tumortherapie auf der basis von substituierten acryloyl-distamycin-derivaten und protein-kinase (serin/threonin-kinase) inhibitoren
UA82322C2 (uk) 2002-07-30 2008-04-10 Центаріс Гмбх Застосування алкілфосфохолінів в комбінації з протипухлинними лікарськими засобами
WO2005000318A2 (en) * 2003-06-23 2005-01-06 Neopharm, Inc. Method of inducing apoptosis and inhibiting cardiolipin synthesis
WO2006081452A2 (en) 2005-01-28 2006-08-03 Robert Birch Co-administration of perifosine with chemotherapeutics
US20070167408A1 (en) 2005-12-19 2007-07-19 Zentaris Gmbh Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
US8383607B2 (en) 2010-03-31 2013-02-26 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hilgard et al. Advances in Experimental Medicine and Biology (1996) vol. 416 pages 157-164 *
Spruss et al. Journal of Cancer Research (1993) vol. 119 no. 3 pages 142-149 *
Stekar et al. European Journal of Cancer (1995) vol. 31A, no. 3 pages 372-374 *

Also Published As

Publication number Publication date
ZA200500453B (en) 2005-08-31
CA2493023C (en) 2012-01-31
EP1545553A1 (de) 2005-06-29
HRP20050184B1 (hr) 2014-04-11
SI1545553T1 (sl) 2011-09-30
US20100190738A1 (en) 2010-07-29
NZ538428A (en) 2006-09-29
CY1111902T1 (el) 2015-11-04
RU2005105693A (ru) 2005-07-10
PL375493A1 (en) 2005-11-28
UA82322C2 (uk) 2008-04-10
US8507710B2 (en) 2013-08-13
JP2005535688A (ja) 2005-11-24
AU2008203060B2 (en) 2011-04-21
KR20130016413A (ko) 2013-02-14
NO335196B1 (no) 2014-10-20
HK1080751A1 (en) 2006-05-04
DK1545553T3 (da) 2011-09-12
TWI332007B (en) 2010-10-21
AR040717A1 (es) 2005-04-20
EP1545553B1 (de) 2011-07-13
PT1545553E (pt) 2011-09-12
KR101066804B1 (ko) 2011-09-22
US8389497B2 (en) 2013-03-05
BR0313048A (pt) 2005-06-14
NO20051040L (no) 2005-02-25
CN1671397A (zh) 2005-09-21
ATE516036T1 (de) 2011-07-15
HRP20050184A2 (en) 2005-04-30
US20100189784A1 (en) 2010-07-29
IL166329A (en) 2012-08-30
TW200404073A (en) 2004-03-16
US8551977B2 (en) 2013-10-08
AU2008203060A1 (en) 2008-07-31
MXPA05001203A (es) 2005-06-08
KR20050026028A (ko) 2005-03-14
AU2003253350A1 (en) 2004-02-23
WO2004012744A1 (de) 2004-02-12
KR20110102485A (ko) 2011-09-16
CA2493023A1 (en) 2004-02-12
EP2301551A1 (de) 2011-03-30
US20040097470A1 (en) 2004-05-20
IL166329A0 (en) 2006-01-15
CN1302780C (zh) 2007-03-07
ES2369535T3 (es) 2011-12-01

Similar Documents

Publication Publication Date Title
AU2008203060B2 (en) Use of alkyl phosphocholines in combination with antitumor medicaments
US5912265A (en) Pharmaceutical compositions containing flavanolignanes and methods for using same as an antiproliferative
RU2671488C2 (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
JP2005501825A (ja) エポシロンを含有する組合せ剤およびその医薬上の使用
AU2011204918B2 (en) Use of alkylphosphocholines in combination with antitumor medicaments
CA2436332A1 (en) Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals
HK1080751B (en) Use of alkyl phosphocholines in combination with antitumor medicaments

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired